Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2026 04:56 ET | Source: Research and Markets

Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Dermatology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The dermatology market is undergoing a...
January 09, 2026 16:05 ET | Source: Alumis Inc.

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 07, 2026 22:52 ET | Source: Alumis Inc.

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Pricing of Upsized Public Offering of Common Stock
January 06, 2026 16:12 ET | Source: Alumis Inc.

Alumis Announces Proposed Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 05, 2026 17:00 ET | Source: Alumis Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
December 19, 2025 09:14 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the...
November 19, 2025 10:50 ET | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 476 Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
November 13, 2025 16:15 ET | Source: Alumis Inc.

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis reports third quarter 2025 financial results and highlights recent progress and anticipated milestones including Phase 3 data in early 1Q 2026
October 24, 2025 09:27 ET | Source: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...